News & Updates

Treatment of symptomatic COVID-19 with nirmatrelvir/ritonavir in children at least 6 years of age who are at risk of progression to severe disease appears to be safe and well-tolerated, with pharmacokinetic data from the open-label phase 2/3 EPIC-Peds* study indicating suitable dosing regimens for two distinct weight categories of this population.

Moderate-to-high intakes of flavonoid result in a reduced risk of chronic obstructive pulmonary disease (COPD) and better lung function, specifically among people with a smoking history, a study has shown.